Balloon sinus dilation for chronic sinusitis

Series
ENT endoscopic procedures
Status
Published
Date
Number of report
053

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for balloon sinus dilation for chronic sinusitis.

Indications include chronic maxillary, frontal and sphenoidal sinusitis.  

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of devices for balloon sinus dilation include:

  • Acclarent Inc (Relieva Spinplus, Relieva Scout)
  • Creganna Medical
  • DALENT Medical (Dalent Medical Sinusleeve)
  • Entellus Medical Inc. (Xpress ENT)
  • InnAccel
  • Jilin Coronado Medical Ltd (PTCA)
  • Medtronic (NuVent EM)
  • Meril Life Sciences Pvt (Mesire, Mozec)
  • Smith & Nephew plc (Ventera)

Table of content is not available at the moment. Report is still ongoing.

17

Apr 2019

The report presents a summary of reimbursement situation for balloon sinus dilation for chronic sinusitis. Indications include chronic maxillary, frontal and sphenoidal sinusitis. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.

Read more

18

Oct 2018

The report presents a summary of reimbursement situation for cochlear implants for hearing loss. The only reimbursement within public / statutory health insurance systems is considered. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland.

Read more
(we accept only company emails)